$3.57
At close: Apr 28 EDT
$3.57
0.000.00%
Pre-Market: 4:00 PM EDT
Comments
Loading...
Fulcrum Therapeutics Analyst Ratings and Price Targets | NASDAQ:FULC | Benzinga
Fulcrum Therapeutics Inc has a consensus price target of $7.5 based on the ratings of 13 analysts. The high is $15 issued by Goldman Sachs on May 14, 2024. The low is $2 issued by B of A Securities on September 12, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., RBC Capital, and HC Wainwright & Co. on February 26, 2025, November 14, 2024, and November 14, 2024, respectively. With an average price target of $4 between HC Wainwright & Co., RBC Capital, and HC Wainwright & Co., there's an implied 12.04% upside for Fulcrum Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
RBC Capital
Leerink Partners
B of A Securities
Stifel
1calculated from analyst ratings
Analyst Ratings for Fulcrum Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/26/2025 | Buy Now | 12.04% | HC Wainwright & Co. | Andrew Fein57% | $4 → $4 | Reiterates | Neutral → Neutral | Get Alert |
| 11/14/2024 | Buy Now | 12.04% | RBC Capital | Gregory Renza47% | $4 → $4 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 11/14/2024 | Buy Now | 12.04% | HC Wainwright & Co. | Andrew Fein57% | $4 → $4 | Reiterates | Neutral → Neutral | Get Alert |
| 09/13/2024 | Buy Now | 12.04% | RBC Capital | Gregory Renza47% | $15 → $4 | Downgrade | Outperform → Sector Perform | Get Alert |
| 09/13/2024 | Buy Now | 12.04% | HC Wainwright & Co. | Andrew Fein57% | $17 → $4 | Downgrade | Buy → Neutral | Get Alert |
| 09/12/2024 | Buy Now | 12.04% | Leerink Partners | Joseph Schwartz65% | → $4 | Downgrade | Outperform → Market Perform | Get Alert |
| 09/12/2024 | Buy Now | -43.98% | B of A Securities | Tazeen Ahmad54% | $10 → $2 | Downgrade | Neutral → Underperform | Get Alert |
| 09/12/2024 | Buy Now | -15.97% | Stifel | Dae Gon Ha47% | $22 → $3 | Downgrade | Buy → Hold | Get Alert |
| 09/12/2024 | Buy Now | — | Cantor Fitzgerald | Kristen Kluska68% | — | Downgrade | Overweight → Neutral | Get Alert |
| 09/09/2024 | Buy Now | 180.11% | B of A Securities | Tazeen Ahmad54% | $5 → $10 | Upgrade | Underperform → Neutral | Get Alert |
| 08/01/2024 | Buy Now | 376.19% | HC Wainwright & Co. | Andrew Fein57% | $17 → $17 | Reiterates | Buy → Buy | Get Alert |
| 07/10/2024 | Buy Now | 544.26% | Cantor Fitzgerald | Kristen Kluska68% | $23 → $23 | Reiterates | Overweight → Overweight | Get Alert |
| 05/20/2024 | Buy Now | 544.26% | Cantor Fitzgerald | Kristen Kluska68% | → $23 | Initiates | → Overweight | Get Alert |
| 05/14/2024 | Buy Now | 376.19% | HC Wainwright & Co. | Andrew Fein57% | $17 → $17 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | 320.17% | Goldman Sachs | Corinne Jenkins48% | $6 → $15 | Upgrade | Neutral → Buy | Get Alert |
| 05/14/2024 | Buy Now | 292.16% | Oppenheimer | Matthew Biegler37% | $16 → $14 | Maintains | Outperform | Get Alert |
| 05/13/2024 | Buy Now | 320.17% | Goldman Sachs | Corinne Jenkins48% | → $15 | Upgrade | Neutral → Buy | Get Alert |
| 03/13/2024 | Buy Now | 292.16% | RBC Capital | Gregory Renza47% | → $14 | Initiates | → Outperform | Get Alert |
| 02/28/2024 | Buy Now | 376.19% | HC Wainwright & Co. | Andrew Fein57% | $14 → $17 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | 320.17% | Piper Sandler | Edward Tenthoff52% | $13 → $15 | Maintains | Overweight | Get Alert |
| 01/26/2024 | Buy Now | 68.07% | Goldman Sachs | Madhu Kumar72% | $5 → $6 | Maintains | Neutral | Get Alert |
| 01/25/2024 | Buy Now | 68.07% | Goldman Sachs | Madhu Kumar72% | $5 → $6 | Maintains | Neutral | Get Alert |
| 09/25/2023 | Buy Now | 40.06% | Goldman Sachs | Madhu Kumar72% | → $5 | Initiates | → Neutral | Get Alert |
| 08/23/2023 | Buy Now | 292.16% | HC Wainwright & Co. | Andrew Fein57% | $5 → $14 | Upgrade | Neutral → Buy | Get Alert |
| 08/22/2023 | Buy Now | 348.18% | Oppenheimer | Matthew Biegler37% | → $16 | Reiterates | Outperform → Outperform | Get Alert |
| 08/22/2023 | Buy Now | 208.12% | Stifel | Dae Gon Ha47% | → $11 | Upgrade | Hold → Buy | Get Alert |
| 08/04/2023 | Buy Now | 40.06% | HC Wainwright & Co. | Andrew Fein57% | → $5 | Reiterates | Neutral → Neutral | Get Alert |
| 05/16/2023 | Buy Now | 348.18% | Oppenheimer | Matthew Biegler37% | $20 → $16 | Maintains | Outperform | Get Alert |
| 05/16/2023 | Buy Now | 40.06% | HC Wainwright & Co. | Andrew Fein57% | $6 → $5 | Maintains | Neutral | Get Alert |
| 05/05/2023 | Buy Now | -15.97% | Goldman Sachs | Madhu Kumar72% | $9 → $3 | Maintains | Neutral | Get Alert |
| 05/04/2023 | Buy Now | -15.97% | Goldman Sachs | Madhu Kumar72% | $9 → $3 | Downgrade | Buy → Neutral | Get Alert |
| 03/13/2023 | Buy Now | 152.1% | Goldman Sachs | Madhu Kumar72% | $17 → $9 | Maintains | Buy | Get Alert |
| 03/10/2023 | Buy Now | 96.08% | Morgan Stanley | Matthew Korn46% | $8 → $7 | Maintains | Equal-Weight | Get Alert |
| 03/10/2023 | Buy Now | 68.07% | HC Wainwright & Co. | Andrew Fein57% | $20 → $6 | Downgrade | Buy → Neutral | Get Alert |
| 03/10/2023 | Buy Now | 124.09% | Credit Suisse | Judah Frommer66% | $11 → $8 | Downgrade | Outperform → Neutral | Get Alert |
| 02/28/2023 | Buy Now | 460.22% | HC Wainwright & Co. | Andrew Fein57% | → $20 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | 124.09% | Morgan Stanley | Matthew Harrison61% | $27 → $8 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 02/27/2023 | Buy Now | 460.22% | HC Wainwright & Co. | Andrew Fein57% | → $20 | Reiterates | → Buy | Get Alert |
| 02/27/2023 | Buy Now | 460.22% | Oppenheimer | Matthew Biegler37% | $26 → $20 | Maintains | Outperform | Get Alert |
| 02/27/2023 | Buy Now | 208.12% | Credit Suisse | Judah Frommer66% | $19 → $11 | Maintains | Outperform | Get Alert |
| 01/24/2023 | Buy Now | 656.3% | Morgan Stanley | Matthew Harrison61% | $26 → $27 | Maintains | Overweight | Get Alert |
| 01/23/2023 | Buy Now | 488.24% | Piper Sandler | Edward Tenthoff52% | $18 → $21 | Maintains | Overweight | Get Alert |
| 01/19/2023 | Buy Now | 376.19% | Goldman Sachs | Madhu Kumar72% | $11 → $17 | Maintains | Buy | Get Alert |
| 11/15/2022 | Buy Now | 208.12% | Goldman Sachs | Madhu Kumar72% | → $11 | Initiates | → Buy | Get Alert |
| 11/14/2022 | Buy Now | 628.29% | Morgan Stanley | Matthew Harrison61% | $25 → $26 | Maintains | Overweight | Get Alert |
| 11/09/2022 | Buy Now | 432.21% | Credit Suisse | Judah Frommer66% | $22 → $19 | Maintains | Outperform | Get Alert |
| 06/13/2022 | Buy Now | 460.22% | HC Wainwright & Co. | Andrew Fein57% | $40 → $20 | Maintains | Buy | Get Alert |
| 05/17/2022 | Buy Now | 600.28% | Morgan Stanley | Matthew Harrison61% | $26 → $25 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Fulcrum Therapeutics (FULC) stock?
The latest price target for Fulcrum Therapeutics (NASDAQ:FULC) was reported by HC Wainwright & Co. on February 26, 2025. The analyst firm set a price target for $4.00 expecting FULC to rise to within 12 months (a possible 12.04% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Fulcrum Therapeutics (FULC)?
The latest analyst rating for Fulcrum Therapeutics (NASDAQ:FULC) was provided by HC Wainwright & Co., and Fulcrum Therapeutics reiterated their neutral rating.
When was the last upgrade for Fulcrum Therapeutics (FULC)?
The last upgrade for Fulcrum Therapeutics Inc happened on September 9, 2024 when B of A Securities raised their price target to $10. B of A Securities previously had an underperform for Fulcrum Therapeutics Inc.
When was the last downgrade for Fulcrum Therapeutics (FULC)?
The last downgrade for Fulcrum Therapeutics Inc happened on September 13, 2024 when RBC Capital changed their price target from $15 to $4 for Fulcrum Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Fulcrum Therapeutics (FULC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fulcrum Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fulcrum Therapeutics was filed on February 26, 2025 so you should expect the next rating to be made available sometime around February 26, 2026.
Is the Analyst Rating Fulcrum Therapeutics (FULC) correct?
While ratings are subjective and will change, the latest Fulcrum Therapeutics (FULC) rating was a reiterated with a price target of $4.00 to $4.00. The current price Fulcrum Therapeutics (FULC) is trading at is $3.57, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
